H.I.G. BioHealth Partners

What H.I.G. BioHealth Partners does

H.I.G. BioHealth Partners, also operating as H.I.G. HealthBridge Capital Partners, is a Miami-based growth-equity investment fund that operates as the dedicated healthcare vertical within the broader H.I.G. Capital, LLC private equity platform. The firm partners with growth-stage healthcare companies across pharma, biotech, medical devices, diagnostics, and related services, providing capital and operational expertise with the stated goal of improving patient outcomes while reducing overall healthcare costs. It was founded in 2011 and is headquartered in Miami, Florida, in the United States.

As a sub-strategy of H.I.G. Capital, which manages $75 billion in assets under management across 18 global offices, more than 500 investment professionals, and over 2,500 cumulative transactions, H.I.G. BioHealth Partners benefits from the parent's capital scale, sourcing infrastructure, and 'Portfolio Operations' value-creation function. Rather than offering a software or technology product, the firm deploys growth equity and pursues active value creation at the portfolio-company level; recent activity includes portfolio company VB Spine's acquisition of Augmedics' augmented-reality spine surgical-navigation platform, announced February 2026 and closed April 2026. The leadership team is anchored by H.I.G. co-founders Sami Mnaymneh and Tony Tamer, with managing directors Aaron Davidson, Bruce Robertson, and Michael Wasserman focused on healthcare.

H.I.G. BioHealth Partners' business model follows standard private-equity economics: management fees on committed or deployed capital generate recurring revenue, supplemented by carried interest from successful exits. Pricing and fund economics are negotiated bilaterally with limited partners and not publicly disclosed. Distribution is conducted through direct institutional relationships with founders and management teams, sourced primarily via the H.I.G. Capital platform's global office network rather than traditional product marketing channels. The firm maintains a limited public marketing footprint, relying on the parent H.I.G. Capital LinkedIn and Twitter presence and selective press releases.

Name

H.I.G. BioHealth Partners

Legal name

H.I.G. Capital, LLC

Website

https://higbio.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

501–1,000 employees

Short description

H.I.G. BioHealth Partners (d/b/a H.I.G. HealthBridge) is a Miami-based growth-equity fund within the H.I.G. Capital platform, investing growth capital in healthcare companies across pharma, biotech, medical devices, diagnostics, and related services.

Ownership category

akta.pro rank

Product category

Healthcare Growth Equity Investment

NAICS

Finance and Insurance (52), Other Financial Investment Activities (5239), Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

akta.pro secondary industry

Healthcare Access & Life Sciences Impact Funds (FSANAJAI)

Keywords

• Growth equity investment
• Healthcare private equity
• Life sciences investing
• Biotech venture capital
• Medical device investment

Headquarters

HQ city

Miami

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Investment Returns and Management Fees: As a private equity and growth equity fund, H.I.G. BioHealth Partners generates returns through capital appreciation from portfolio company investments, typically realized through strategic exits, and collects management fees from fund operations.

Distribution channels1 record

Marketing channels3 records

Core offering

H.I.G. BioHealth Partners (operating as H.I.G. HealthBridge Capital Partners) is a private growth equity fund and wholly-owned subsidiary of H.I.G. Capital, LLC that invests growth-stage capital in healthcare companies spanning pharmaceuticals, biotechnology, medical devices, diagnostics, and related services. The firm partners with management teams to scale growth-stage healthcare businesses, with the stated objective of improving patient outcomes and reducing healthcare costs, while providing operating-partner expertise through the broader H.I.G. Capital platform.

Product overview

H.I.G. HealthBridge is a growth equity fund that operates as part of the H.I.G. Capital platform. The fund provides growth capital to healthcare companies in pharma, biotech, medical devices, diagnostics, and related services. Rather than offering a unified software platform, the investment thesis centers on portfolio company partnerships where H.I.G. HealthBridge provides capital and operational expertise. The portfolio includes companies like VB Spine (augmented reality spine surgery navigation) and spans multiple healthcare subsectors.

Differentiator

Problem solved

Functional benefit

Products and services

• H.I.G. HealthBridge Capital Partners Growth Equity Fund A private growth equity fund that invests growth-stage capital in healthcare companies across pharmaceuticals, biotechnology, medical devices, diagnostics, and related services, while providing operating-partner support for value creation, with the objective of improving patient outcomes and reducing healthcare costs. The product is offered to limited partners (institutional investors) as a commingled fund and to growth-stage healthcare companies as growth equity capital.
• Value Creation and Portfolio Operations Program An operating-partner program provided to portfolio companies alongside growth equity capital, designed to support strategic initiatives, operational improvements, and value creation. The program targets management teams of growth-stage healthcare businesses receiving investment from the fund.

Quantifiable outcome

• 400 leading companies in past and present private equity portfolio

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators4 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Bain Capital Life Sciences: The dedicated life sciences franchise of Bain Capital, investing across biopharma, medtech, and healthcare technology. Comparable as a healthcare-specialist sponsor within a larger multi-strategy platform, analogous to H.I.G. BioHealth Partners' position within H.I.G. Capital.
• TPG Capital (Healthcare): TPG's healthcare-dedicated investing activity spans pharma, medtech, and healthcare services across growth and buyout stages. Comparable as a healthcare specialist arm of a major global alternative asset manager competing for similar growth-stage healthcare opportunities.
• The Carlyle Group (Healthcare): Carlyle's healthcare-focused investing across pharma, biotech, medical devices, and healthcare services. Comparable as a healthcare vertical within a global multi-strategy platform competing for similar growth-stage healthcare companies.
• KKR Health Care Strategic Growth: The healthcare growth strategy of KKR, investing in growth-stage healthcare companies across biopharma, medical devices, and digital health. Comparable as a healthcare growth platform housed within a global multi-strategy PE firm, similar to H.I.G. BioHealth Partners' structure.

Direct peers

• Avista Capital Partners: A middle-market private equity firm with a dedicated healthcare focus across pharma, medical devices, and healthcare services. Comparable to H.I.G. BioHealth Partners in stage focus, sector concentration, and middle-market healthcare deal profile.
• Linden Capital Partners: A healthcare-focused private equity firm investing in middle-market healthcare companies across pharma services, medical products, and healthcare services. Directly comparable to H.I.G. BioHealth Partners as a sector-specialist growth/buyout sponsor in the same healthcare subsegments.
• Ampersand Capital Partners: A healthcare-focused private equity firm specializing in growth equity and buyouts in life sciences, diagnostics, medical devices, and pharma services. Closely comparable in stage focus (growth-oriented), sector concentration, and check size to H.I.G. BioHealth Partners.
• Arsenal Capital Partners: A private equity firm investing in healthcare and specialty industrials, with significant healthcare exposure across services, pharma services, and medical products. Comparable in middle-market focus and healthcare vertical specialization.
• Welsh, Carson, Anderson & Stowe (WCAS): A long-established healthcare-dedicated private equity firm investing across healthcare services, pharma, medical devices, and technology-enabled care. Comparable as a healthcare-specialist sponsor with growth and buyout strategies targeting similar portfolio company profiles.
• Genstar Capital: A middle-market private equity firm with active healthcare investing across pharma services, medical devices, and healthcare technology. Comparable to H.I.G. BioHealth Partners in stage focus, middle-market healthcare deal profile, and growth-oriented strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/HIGCapitalLLC
• LinkedInlinkedin.com/company/164187

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments26 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about H.I.G. BioHealth Partners